E. Samantas

发表

Paclitaxel and gemcitabine versus carboplatin and gemcitabine in patients with advanced non-small-cell lung cancer. A phase III study of the Hellenic Cooperative Oncology Group.

M. Dimopoulos, K. Syrigos, I. Boukovinas, 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

Potential value of PTEN in predicting cetuximab response in colorectal cancer: An exploratory study

G. Fountzilas, P. Kosmidis, D. Skarlos, 2008, BMC Cancer.

Effects of epoetin-alpha on quality of life of cancer patients with solid tumors receiving chemotherapy.

U. Dafni, G. Aravantinos, G. Fountzilas, 2009, Anticancer research.

Induction chemotherapy followed by concomitant radiotherapy and weekly cisplatin versus the same concomitant chemoradiotherapy in patients with nasopharyngeal carcinoma: a randomized phase II study conducted by the Hellenic Cooperative Oncology Group (HeCOG) with biomarker evaluation.

T. Ciuleanu, G. Fountzilas, K. Markou, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

Prevalence of BRCA1 mutations among 403 women with triple-negative breast cancer: implications for genetic screening selection criteria: a Hellenic Cooperative Oncology Group Study

F. Fostira, D. Yannoukakos, H. Gogas, 2012, Breast Cancer Research and Treatment.

Expression of angiogenic markers in the peripheral blood of patients with advanced breast cancer treated with weekly docetaxel.

G. Fountzilas, D. Pectasides, H. Linardou, 2012, Anticancer research.

Paclitaxel (175 mg/m2) plus carboplatin (6 AUC) versus paclitaxel (225 mg/m2) plus carboplatin (6 AUC) in advanced non-small-cell lung cancer (NSCLC): a multicenter randomized trial. Hellenic Cooperative Oncology Group (HeCOG).

M. Dimopoulos, N. Pavlidis, C. Papadimitriou, 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

Impact of Bevacizumab Versus Erlotinib on Tumor Metrics in Patients With Previously Untreated Advanced Non-small Cell Lung Cancer: A Study by the Hellenic Cooperative Oncology Group

G. Fountzilas, P. Kosmidis, G. Mountzios, 2020, Anticancer Research.

A randomised phase III trial of adjuvant radio-chemotherapy comparing Irinotecan, 5FU and Leucovorin to 5FU and Leucovorin in patients with rectal cancer: a Hellenic Cooperative Oncology Group Study.

C. Papadimitriou, T. Economopoulos, H. Kalofonos, 2008, European journal of cancer.

Paclitaxel and gemcitabine versus paclitaxel and vinorelbine in patients with advanced non-small-cell lung cancer. A phase III study of the Hellenic Cooperative Oncology Group (HeCOG).

M. Dimopoulos, K. Syrigos, H. Kalofonos, 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

A prospective randomized phase III study in non-small-cell lung cancer comparing cisplatin, ifosfamide, vinblastine (VIP) versus cisplatin, ifosfamide and etoposide (VIP-16). Hellenic Co-Operative Oncology Group.

N. Pavlidis, G. Fountzilas, P. Kosmidis, 1996, Annals of oncology : official journal of the European Society for Medical Oncology.

Fluorouracil and leucovorin with or without interferon alfa-2b in advanced colorectal cancer: analysis of a prospective randomized phase III trial. Hellenic Cooperative Oncology Group.

N. Pavlidis, G. Fountzilas, P. Kosmidis, 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

An out-patient second-line chemotherapy with gemcitabine and vinorelbine in patients with non-small cell lung cancer previously treated with cisplatin-based chemotherapy. A phase II study of the Hellenic co-operative Oncology Group.

H. Kalofonos, G. Fountzilas, D. Pectasides, 2001, Anticancer research.

Phase I study of etoposide, cisplatin and irinotecan triplet in patients with advanced-stage small-cell lung cancer

M. Dimopoulos, N. Pavlidis, H. Kalofonos, 2005, Cancer Chemotherapy and Pharmacology.

Postoperative dose-dense sequential chemotherapy with epirubicin, paclitaxel and CMF in patients with high-risk breast cancer: safety analysis of the Hellenic Cooperative Oncology Group randomized phase III trial HE 10/00.

U. Dafni, H. Gogas, C. Markopoulos, 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

Heterogeneity of circulating tumor cells (CTCs) in patients with recurrent small cell lung cancer (SCLC) treated with pazopanib.

V. Georgoulias, M. Plataki, E. Samantas, 2017, Lung cancer.

Randomized comparison of etoposide-cisplatin vs. etoposide-carboplatin and irradiation in small-cell lung cancer. A Hellenic Co-operative Oncology Group study.

G. Fountzilas, P. Kosmidis, D. Skarlos, 1994, Annals of oncology : official journal of the European Society for Medical Oncology.

Cisplatin/etoposide versus carboplatin/etoposide chemotherapy and irradiation in small cell lung cancer: a randomized phase III study. Hellenic Cooperative Oncology Group for Lung Cancer Trials.

N. Pavlidis, G. Fountzilas, P. Kosmidis, 1994, Seminars in oncology.

Prospective, open-label, randomized, phase III study of two dose-dense regimens MVAC versus gemcitabine/cisplatin in patients with inoperable, metastatic or relapsed urothelial cancer: a Hellenic Cooperative Oncology Group study (HE 16/03).

M. Dimopoulos, U. Dafni, A. Psyrri, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

Combination chemotherapy with paclitaxel plus carboplatin versus paclitaxel plus gemcitabine in inoperable non-small cell lung cancer: a phase III randomized study. Preliminary results. Hellenic Cooperative Oncology Group.

N. Pavlidis, G. Fountzilas, P. Kosmidis, 2000, Seminars in Oncology.

Multicenter phase-II trial of irinotecan plus oxaliplatin [IROX regimen] in patients with poor-prognosis cancer of unknown primary: a hellenic cooperative oncology group study

M. Dimopoulos, N. Pavlidis, G. Fountzilas, 2008, Cancer Chemotherapy and Pharmacology.

Epithelial ovarian cancer in Greece: a retrospective study of 1,791 patients by the Hellenic Cooperative Oncology Group (HeCOG).

M. Dimopoulos, N. Pavlidis, T. Economopoulos, 2009, Anticancer research.

A pharmacokinetic binding model for bevacizumab and VEGF165 in colorectal cancer patients

G. Patrinos, G. Aravantinos, H. Kalofonos, 2015, Cancer Chemotherapy and Pharmacology.

Bcl2 and p53 protein expression in metastatic carcinoma of unknown primary origin: biological and clinical implications. A Hellenic Co-operative Oncology Group study.

N. Pavlidis, G. Fountzilas, P. Kosmidis, 1998, Anticancer research.

Correlation of in vitro cytotoxicity and clinical response to chemotherapy in ovarian and breast cancer patients.

N. Chondrogianni, E. Gonos, E. Samantas, 2001, Anticancer research.

Investigation of prognostic biomarkers in patients with urothelial carcinoma treated with platinum-based regimens.

F. Fostira, A. Charchanti, A. Psyrri, 2022, Urologic oncology.

Angiogenic and Antiangiogenic VEGFA Splice Variants in Colorectal Cancer: Prospective Retrospective Cohort Study in Patients Treated With Irinotecan-Based Chemotherapy and Bevacizumab.

K. Papadopoulou, G. Fountzilas, G. Pentheroudakis, 2019, Clinical colorectal cancer.

The combination of bevacizumab/temsirolimus after first-line anti-VEGF therapy in advanced renal-cell carcinoma: a clinical and biomarker study

M. Dimopoulos, G. Aravantinos, K. Koutsoukos, 2018, International Journal of Clinical Oncology.

Prospective, open-label, randomized, phase III study of two dose-dense regimens MVAC versus gemcitabine/ cisplatin in patients with inoperable, metastatic or relapsed urothelial cancer: a Hellenic Cooperative Oncology Group study

U. Dafni, G. Fountzilas, A. Bamias, 2013 .

Gemcitabine Combined with the mTOR Inhibitor Temsirolimus in Patients with Locally Advanced or Metastatic Pancreatic Cancer. A Hellenic Cooperative Oncology Group Phase I/II Study

G. Fountzilas, G. Pentheroudakis, C. Dervenis, 2018, Targeted Oncology.

First Line Gemcitabine/Pazopanib in Locally Advanced and/or Metastatic Biliary Tract Carcinoma. A Hellenic Cooperative Oncology Group Phase II Study

G. Aravantinos, A. Psyrri, G. Fountzilas, 2020, AntiCancer Research.

Lapatinib with whole brain radiotherapy in patients with brain metastases from breast and non-small cell lung cancer: a phase II study of the Hellenic Cooperative Oncology Group (HeCOG)

K. Syrigos, G. Fountzilas, C. Papandreou, 2017, Journal of Neuro-Oncology.

Non-small cell lung cancer in the young: a retrospective analysis of diagnosis, management and outcome data.

N. Pavlidis, K. Syrigos, G. Fountzilas, 2006, Anticancer research.

Dose-Dense Sequentials Chemotherapy with Epirubicin and Paclitaxel in Advanced Breast Cancer

N. Pavlidis, C. Papadimitriou, C. Papadimitriou, 2001, Cancer investigation.

Paclitaxel (175 mg/m2) plus carboplatin versus paclitaxel (225 mg/m2) plus carboplatin in non-small cell lung cancer: a randomized study.

N. Pavlidis, G. Fountzilas, P. Kosmidis, 1997, Seminars in oncology.

Gemcitabine and vinorelbine as second-line treatment in patients with metastatic breast cancer progressing after first-line taxane-based chemotherapy: a phase II study conducted by the Hellenic Cooperative Oncology Group.

M. Dimopoulos, N. Pavlidis, G. Fountzilas, 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

Combination chemotherapy with cisplatin, etoposide and irinotecan in patients with extensive small-cell lung cancer: A phase II study of the Hellenic Co-operative Oncology Group.

M. Dimopoulos, K. Syrigos, T. Economopoulos, 2007, Lung cancer.

Vascular endothelial growth factor polymorphisms and clinical outcome in patients with metastatic breast cancer treated with weekly docetaxel

C. Papadimitriou, H. Kalofonos, K. Papadopoulou, 2013, The Pharmacogenomics Journal.

Combination chemotherapy with paclitaxel and gemcitabine followed by concurrent chemoradiotherapy in non-operable localized non-small cell lung cancer. A hellenic cooperative oncology group (HeCOG) phase II study.

N. Pavlidis, H. Gogas, G. Fountzilas, 2007, Anticancer research.

Original Paclitaxel (175 mg/m 2 ) plus carboplatin (6 AUC) versus paclitaxel (225 mg/m ) plus carboplatin (6 AUC) in advanced non-small-cell lung cancer (NSCLC): A multicenter randomized trial

C. Papadimitriou, D. Skarlos, E. Samantas, 2005 .

An individual patient-data meta-analysis of metronomic oral vinorelbine in metastatic non-small cell lung cancer

M. Mencoboni, G. Banna, J. Daurès, 2019, PloS one.

A multicenter randomized trial of paclitaxel (175 mg/m2) plus carboplatin (6AUC) versus paclitaxel (225 mg/m2) plus carboplatin (6AUC) in advanced non-small cell lung cancer (NSCLC)

N. Pavlidis, C. Papadimitriou, G. Fountzilas, 1999 .

Non Small Cell Lung Cancer in the Elderly: Clinico-Pathologic, Management and Outcome Characteristics in Comparison to Younger Patients

T. Economopoulos, G. Fountzilas, D. Pectasides, 2009, Journal of chemotherapy.

Prognostic significance of RACGAP1 mRNA expression in high-risk early breast cancer: a study in primary tumors of breast cancer patients participating in a randomized Hellenic Cooperative Oncology Group trial

G. Fountzilas, N. Pavlidis, H. Gogas, 2012, Cancer Chemotherapy and Pharmacology.

Accelerated Bifractionated Radiation with Concurrent Cisplatin Administration in Locally Advanced Head and Neck Cancer: A Feasibility Study

G. Fountzilas, A. Nikolaou, D. Skarlos, 1997, Tumori.

Radiation and Concurrent Carboplatin Administration in Locally Advanced Head and Neck Cancer

G. Fountzilas, A. Nikolaou, D. Skarlos, 1995, Tumori.

Radiation therapy and concurrent cisplatin administration in locally advanced head and neck cancer. A Hellenic Co-operative Oncology Group study.

S. Papaspyrou, G. Fountzilas, P. Kosmidis, 1994, Acta oncologica.

Association of Notch and Hedgehog Pathway Activation With Prognosis in Early-stage Colorectal Cancer

G. Fountzilas, K. Petraki, D. Pectasides, 2019, AntiCancer Research.

TP53 mutations and protein immunopositivity may predict for poor outcome but also for trastuzumab benefit in patients with early breast cancer treated in the adjuvant setting

M. Dimopoulos, E. Giannoulatou, H. Gogas, 2016, Oncotarget.

Prognostic implications of mismatch repair deficiency in patients with nonmetastatic colorectal and endometrial cancer

A. Psyrri, G. Fountzilas, G. Pentheroudakis, 2019, ESMO Open.

Long-term survival data and prognostic factors of a complete response to chemotherapy in patients with head and neck cancer treated with platinum-based induction chemotherapy: a Hellenic Co-operative oncology Group study.

G. Fountzilas, A. Nikolaou, P. Kosmidis, 1997, Medical and pediatric oncology.

Carboplatin plus paclitaxel in unknown primary carcinoma: a phase II Hellenic Cooperative Oncology Group Study.

N. Pavlidis, H. Kalofonos, G. Fountzilas, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Randomized phase III clinical trial comparing the combination of capecitabine and oxaliplatin (CAPOX) with the combination of 5-fluorouracil, leucovorin and oxaliplatin (modified FOLFOX6) as adjuvant therapy in patients with operated high-risk stage II or stage III colorectal cancer

G. Fountzilas, G. Pentheroudakis, C. Scopa, 2015, BMC Cancer.

Postoperative dose-dense sequential versus concomitant administration of epirubicin and paclitaxel in patients with node-positive breast cancer: 5-year results of the Hellenic Cooperative Oncology Group HE 10/00 phase III Trial

M. Dimopoulos, U. Dafni, H. Gogas, 2012, Breast Cancer Research and Treatment.

Ixabepilone Administered Weekly or Every Three Weeks in HER2-Negative Metastatic Breast Cancer Patients; A Randomized Non-Comparative Phase II Trial

C. Papadimitriou, G. Fountzilas, G. Pentheroudakis, 2013, PloS one.

Associations of angiogenesis-related proteins with specific prognostic factors, breast cancer subtypes and survival outcome in early-stage breast cancer patients. A Hellenic Cooperative Oncology Group (HeCOG) trial

M. Dimopoulos, H. Gogas, G. Lazaridis, 2018, PloS one.

Mutations of the epidermal growth factor receptor tyrosine kinase domain and associations with clinicopathological features in non-small cell lung cancer patients.

G. Fountzilas, D. Pectasides, H. Linardou, 2006, Lung cancer.

Paclitaxel plus carboplatin versus gemcitabine plus paclitaxel in advanced non-small-cell lung cancer: a phase III randomized trial.

M. Dimopoulos, G. Fountzilas, P. Kosmidis, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Postoperative radiation and concomitant bolus fluorouracil with or without additional chemotherapy with fluorouracil and high-dose leucovorin in patients with high-risk rectal cancer: a randomized phase III study conducted by the Hellenic Cooperative Oncology Group.

U. Dafni, N. Pavlidis, G. Fountzilas, 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

Combination chemotherapy with low doses of weekly Carboplatin and oral Etoposide in poor risk small cell lung cancer.

N. Pavlidis, H. Kalofonos, G. Fountzilas, 1999, Lung cancer.

A comparative study of cisplatin and vinblastine versus ifosfamide, cisplatin and vinblastine in non-operable non-small-cell lung cancer. A study of the Hellenic Co-operative Oncology Group for Lung Cancer Trials.

G. Fountzilas, P. Kosmidis, D. Skarlos, 1994, Annals of oncology : official journal of the European Society for Medical Oncology.

Treatment of intermediate‐ and high‐grade non‐Hodgkin's lymphoma using CEOP versus CNOP

N. Pavlidis, T. Economopoulos, G. Fountzilas, 2002, European journal of haematology.

A randomized phase III study comparing three anthracycline-free taxane-based regimens, as first line chemotherapy, in metastatic breast cancer

M. Dimopoulos, U. Dafni, H. Gogas, 2009, Breast Cancer Research and Treatment.

Evaluation of the prognostic role of centromere 17 gain and HER2/topoisomerase II alpha gene status and protein expression in patients with breast cancer treated with anthracycline-containing adjuvant chemotherapy: pooled analysis of two Hellenic Cooperative Oncology Group (HeCOG) phase III trials

M. Dimopoulos, U. Dafni, N. Pavlidis, 2013, BMC Cancer.

Thalidomide and dexamethasone combination for refractory multiple myeloma.

M. Dimopoulos, K. Zervas, C. Papadimitriou, 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

Temozolomide in combination with docetaxel in patients with advanced melanoma: a phase II study of the Hellenic Cooperative Oncology Group.

H. Gogas, G. Fountzilas, D. Skarlos, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Temozolomide i n C ombination W ith D ocetaxel i n P atients With A dvanced M elanoma: A P hase I I S tudy o f t he Hellenic C ooperative O ncology G roup

H. Gogas, G. Fountzilas, P. Kosmidis, 2002 .

Evaluation of the prognostic value of CD3, CD8, and FOXP3 mRNA expression in early‐stage breast cancer patients treated with anthracycline‐based adjuvant chemotherapy

M. Dimopoulos, H. Gogas, R. Wirtz, 2018, Cancer medicine.

Phase II study of panitumumab combined with capecitabine and oxaliplatin as first-line treatment in metastatic colorectal cancer patients: clinical results including extended tumor genotyping

K. Syrigos, E. Giannoulatou, G. Fountzilas, 2018, Medical Oncology.

A randomized phase III study of adjuvant platinum/docetaxel chemotherapy with or without radiation therapy in patients with gastric cancer

G. Fountzilas, M. Dimopoulos, G. Fountzilas, 2010, Cancer Chemotherapy and Pharmacology.

Phase II study of temozolomide in heavily pretreated cancer patients with brain metastases.

P. Kosmidis, D. Skarlos, A. Bamias, 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

Second-line pazopanib in patients with relapsed and refractory small-cell lung cancer: a multicentre phase II study of the Hellenic Oncology Research Group

V. Georgoulias, G. Fountzilas, S. Agelaki, 2017, British Journal of Cancer.

Weekly alternating non-cross-resistant chemotherapy for small cell lung cancer with a good prognosis: a study of the Hellenic Cooperative Oncology Group.

N. Pavlidis, G. Fountzilas, D. Pectasides, 1999, American journal of clinical oncology.

Docetaxel and cisplatin with granulocyte colony-stimulating factor (G-CSF) versus MVAC with G-CSF in advanced urothelial carcinoma: a multicenter, randomized, phase III study from the Hellenic Cooperative Oncology Group.

M. Dimopoulos, C. Papadimitriou, C. Papadimitriou, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Paclitaxel and gemcitabine in advanced non-nasopharyngeal head and neck cancer: a phase II study conducted by the Hellenic Cooperative Oncology Group.

N. Pavlidis, C. Papadimitriou, G. Fountzilas, 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

Expression of a molecular marker panel as a prognostic tool in gastric cancer patients treated postoperatively with docetaxel and irinotecan. A study of the Hellenic Cooperative Oncology Group.

G. Fountzilas, A. Goussia, D. Skarlos, 2007, Anticancer research.

Carboplatin plus gemcitabine in patients with inoperable or metastatic pancreatic cancer: a phase II multicenter study by the Hellenic Cooperative Oncology Group.

H. Gogas, T. Economopoulos, E. Kastritis, 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

Concomitant radiochemotherapy vs radiotherapy alone in patients with head and neck cancer

George Fountzilas, Tudor Ciuleanu, Thomas Zaraboukas, 2004, Medical oncology.

Expression profiling of 21 biomolecules in locally advanced nasopharyngeal carcinomas of Caucasian patients

V. Vassiliou, G. Fountzilas, E. Samantas, 2013, BMC Clinical Pathology.

Randomized comparison of early versus late hyperfractionated thoracic irradiation concurrently with chemotherapy in limited disease small-cell lung cancer: a randomized phase II study of the Hellenic Cooperative Oncology Group (HeCOG).

N. Pavlidis, H. Kalofonos, D. Kardamakis, 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

Definite radiation and concomitant Cisplatin administration in locally advanced head and neck cancer

G. Fountzilas, P. Kosmidis, D. Skarlos, 1994 .

Paclitaxel by three-hour infusion and carboplatin in advanced carcinoma of nasopharynx and other sites of the head and neck. A phase II study conducted by the Hellenic Cooperative Oncology Group.

N. Pavlidis, G. Fountzilas, P. Kosmidis, 1997, Annals of oncology : official journal of the European Society for Medical Oncology.

A randomized phase III trial of adjuvant chemotherapy with irinotecan, leucovorin and fluorouracil versus leucovorin and fluorouracil for stage II and III colon cancer: A Hellenic Cooperative Oncology Group study

M. Dimopoulos, G. Aravantinos, T. Economopoulos, 2011, BMC medicine.

Prognostic Significance of ESR1 Gene Amplification, mRNA/Protein Expression and Functional Profiles in High-Risk Early Breast Cancer: A Translational Study of the Hellenic Cooperative Oncology Group (HeCOG)

M. Dimopoulos, N. Pavlidis, H. Gogas, 2013, PloS one.

Cisplatin/etoposide versus carboplatin/etoposide chemotherapy and irradiation in small cell lung cancer :f a randomized phase III study

N. Pavlidis, G. Fountzilas, P. Kosmidis, 1994 .

Paclitaxel and carboplatin in recurrent or metastatic head and neck cancer: a phase II study.

G. Fountzilas, A. Nikolaou, D. Skarlos, 1997, Seminars in oncology.

Posterior Reversible Encephalopathy Syndrome With Concurrent Nephrotic Syndrome in a Patient Treated With Pazopanib for Metastatic Renal Cell Carcinoma: Case Report and Review of the Literature

G. Papaxoinis, E. Samantas, A. Visvikis, 2017, Clinical genitourinary cancer.

AGAPP: efficacy of first-line cisplatin, 5-fluorouracil with afatinib in inoperable gastric and gastroesophageal junction carcinomas. A Hellenic Cooperative Oncology Group study

G. Aravantinos, C. Petraki, A. Psyrri, 2021, Acta oncologica.

Pathogenic mutations and overall survival in 3,084 patients with cancer: the Hellenic Cooperative Oncology Group Precision Medicine Initiative

E. Giannoulatou, H. Gogas, Jianhua Zhang, 2020, Oncotarget.

EGFR gene gain and PTEN protein expression are favorable prognostic factors in patients with KRAS wild-type metastatic colorectal cancer treated with cetuximab

S. Tejpar, A. Psyrri, G. Fountzilas, 2014, Journal of Cancer Research and Clinical Oncology.

Clinical Significance of Germline Cancer Predisposing Variants in Unselected Patients with Pancreatic Adenocarcinoma

F. Fostira, C. Papadimitriou, G. Aravantinos, 2021, Cancers.

Dose-dense sequential adjuvant chemotherapy followed, as indicated, by trastuzumab for one year in patients with early breast cancer: first report at 5-year median follow-up of a Hellenic Cooperative Oncology Group randomized phase III trial

M. Dimopoulos, U. Dafni, N. Pavlidis, 2014, BMC Cancer.

Dose selection trial of metronomic oral vinorelbine monotherapy in patients with metastatic cancer: a hellenic cooperative oncology group clinical translational study

I. Boukovinas, G. Aravantinos, G. Fountzilas, 2013, BMC Cancer.

Genetic mapping of pancreatic cancer by targeted next-generation sequencing in a cohort of patients managed with nab-paclitaxel-based chemotherapy or agents targeting the EGFR axis: a retrospective analysis of the Hellenic Cooperative Oncology Group (HeCOG)

K. Papadopoulou, G. Fountzilas, G. Pentheroudakis, 2019, ESMO Open.

Prognostic factors in Greek patients with small cell lung cancer (SCLC). A Hellenic Cooperative Oncology Group study.

N. Pavlidis, H. Kalofonos, G. Fountzilas, 2002, Anticancer research.

ABREAST: a prospective, real-world study on the effect of nab-paclitaxel treatment on clinical outcomes and quality of life of patients with metastatic breast cancer

C. Papadimitriou, G. Aravantinos, A. Psyrri, 2020, Breast Cancer Research and Treatment.

A study of gene expression markers for predictive significance for bevacizumab benefit in patients with metastatic colon cancer: a translational research study of the Hellenic Cooperative Oncology Group (HeCOG)

N. Pavlidis, G. Fountzilas, G. Pentheroudakis, 2014, BMC Cancer.

Paclitaxel in combination with carboplatin or gemcitabine for the treatment of advanced head and neck cancer.

N. Pavlidis, G. Fountzilas, P. Kosmidis, 1997, Seminars in oncology.

Disease evolution and heterogeneity in bilateral breast cancer.

F. Fostira, E. Giannoulatou, K. Papadopoulou, 2016, American journal of cancer research.

Adjuvant Cytotoxic and Endocrine Therapy in Pre- and Postmenopausal Patients With Breast Cancer and One to Nine Infiltrated Nodes: Five-Year Results of the Hellenic Cooperative Oncology Group Randomized HE 10/92 Study

K. Kyriakou, A. Adamou, N. Pavlidis, 2004, American journal of clinical oncology.

Irinotecan or oxaliplatin combined with leucovorin and 5-fluorouracil as first-line treatment in advanced colorectal cancer: a multicenter, randomized, phase II study.

M. Dimopoulos, T. Economopoulos, H. Kalofonos, 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

Expression Patterns of Growth and Survival Genes with Prognostic Implications in Advanced Pancreatic Cancer.

G. Fountzilas, G. Pentheroudakis, C. Dervenis, 2016, Anticancer research.

G. Fountzilas, G. Pentheroudakis, C. Scopa, 2015, BMC Cancer.

Prospective, randomized phase III study comparing two intensified regimens (methotrexate/vinblastine/doxorubicin hydrochloride/cisplatin [MVAC] versus gemcitabine/cisplatin) in patients with inoperable or recurrent urothelial cancer.

M. Dimopoulos, A. Bamias, E. Kostouros, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Tumors with high-density tumor infiltrating lymphocytes constitute a favorable entity in breast cancer: a pooled analysis of four prospective adjuvant trials

H. Gogas, G. Aravantinos, A. Psyrri, 2015, Oncotarget.

A multicentre phase II trial of cabazitaxel in patients with advanced non-small-cell lung cancer progressing after docetaxel-based chemotherapy

V. Georgoulias, D. Mavroudis, I. Varthalitis, 2016, British Journal of Cancer.

Phase II study of pegylated liposomal doxorubicin: inactive in recurrent small-cell lung cancer. A Hellenic Cooperative Oncology Group Study.

H. Kalofonos, G. Fountzilas, P. Kosmidis, 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

Dose selection trial of metronomic oral vinorelbine monotherapy in patients with metastatic cancer: a hellenic cooperative oncology group clinical translational study

I. Boukovinas, G. Aravantinos, G. Fountzilas, 2013, BMC Cancer.

Association of low Syndecan-1 expression with adverse histopathological parameters in gastric carcinomas.

A. Charchanti, P. Kanavaros, P. Papakostas, 2019, Journal of B.U.ON. : official journal of the Balkan Union of Oncology.

Patterns of practice and pharmacoeconomic analysis of the management of patients with metastatic renal cell carcinoma (mRCC) in Greece––the CRISIS study. A retrospective analysis by the Hellenic Genitourinary Cancer Group (HGUCG)

M. Dimopoulos, A. Papatsoris, G. Aravantinos, 2018, Expert review of pharmacoeconomics & outcomes research.

Safety and Tolerability of Anthracycline-Containing Adjuvant Chemotherapy in Elderly High-Risk Breast Cancer Patients.

M. Dimopoulos, H. Gogas, G. Aravantinos, 2016, Clinical breast cancer.

AMALTHEA: Prospective, Single‐Arm Study of the Hellenic Cooperative Oncology Group (HeCOG) Evaluating Efficacy and Safety of First‐Line FOLFIRI + Aflibercept for 6 Months Followed by Aflibercept Maintenance in Patients With Metastatic Colorectal Cancer

G. Aravantinos, C. Petraki, G. Fountzilas, 2018, Clinical colorectal cancer.

Pulmonary Langerhans cell histiocytosis in a patient previously treated for germ cell tumor.

G. Aravantinos, P. Argyriou, J. Sgouros, 2010, Journal of B.U.ON. : official journal of the Balkan Union of Oncology.

Survivin and glycodelin transcriptional activity in node-positive early breast cancer: mRNA expression of two key regulators of cell survival

M. Dimopoulos, N. Pavlidis, H. Gogas, 2006, Breast Cancer Research and Treatment.

Association of VEGF-A splice variant mRNA expression with outcome in bevacizumab-treated patients with metastatic breast cancer.

M. Dimopoulos, G. Fountzilas, G. Pentheroudakis, 2014, Clinical breast cancer.

First line treatment with docetaxel (D) and gemcitabine (G) in patients with inoperable pancreatic cancer: a multicenter phase II study

G. Fountzilas, D. Mavroudis, N. Tsavaris, 1999 .

Association of VEGF-A splice variant mRNA expression with outcome in bevacizumab-treated patients with metastatic breast cancer.

M. Dimopoulos, G. Fountzilas, G. Pentheroudakis, 2014, Clinical Breast Cancer.

Paclitaxel and carboplatin in inoperable non-small-cell lung cancer: a phase II study.

N. Pavlidis, G. Fountzilas, P. Kosmidis, 1997, Annals of oncology : official journal of the European Society for Medical Oncology.

Views of cancer patients regarding cardiopulmonary resuscitation in Greece

I. Siafaka, N. Iacovidou, A. Chalkias, 2018, European journal of cancer care.

Paclitaxel and gemcitabine vs carboplatin and gemcitabine. A multicenter, phase III randomized trial in patients with advanced inoperable non-small cell lung cancer (NSCLC)

K. Syrigos, G. Fountzilas, P. Kosmidis, 2005 .

Cutaneous toxicities of antineoplastic agents: data from a large cohort of Greek patients

G. Aravantinos, K. Syrigos, A. Bamias, 2019, Supportive Care in Cancer.